Janus Henderson Global Life Sciences benefits from an exceptional lead manager, strong support resources, and a consistently applied robust investment process with prudent risk management, underpinning its Above Average People and Process Pillar ratings.
Janus Henderson Global Life Sciences Fund Class I JFNIX
- NAV / 1-Day Return 82.51 / +0.19 %
- Total Assets 5.4B
-
Adj. Expense Ratio
0.780%
- Expense Ratio 0.780%
- Distribution Fee Level Below Average
- Share Class Type Institutional
- Category Health
- Investment Style Large Blend
- Min. Initial Investment 2,500
- Status Open
- TTM Yield 0.45%
- Turnover 30%
USD | NAV as of Jun 13, 2026 | 1-Day Return as of Jun 13, 2026, 12:11 AM GMT+0
Morningstar’s Analysis JFNIX
Will JFNIX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the JFNIX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of JFNIX’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 40.7
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 8.89 | 461M | Healthcare |
Johnson & Johnson | 7.31 | 379M | Healthcare |
AstraZeneca PLC | 4.60 | 239M | Healthcare |
AbbVie Inc | 4.09 | 212M | Healthcare |
UnitedHealth Group Inc | 3.14 | 163M | Healthcare |
Novartis AG ADR | 2.86 | 148M | Healthcare |
Thermo Fisher Scientific Inc | 2.51 | 130M | Healthcare |
Praxis Precision Medicines Inc Ordinary Shares | 2.45 | 127M | Healthcare |
argenx SE ADR | 2.41 | 125M | Healthcare |
Abbott Laboratories | 2.40 | 124M | Healthcare |
United States